CL2019003485A1 - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy. (divisional request 201900909) - Google Patents

Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy. (divisional request 201900909)

Info

Publication number
CL2019003485A1
CL2019003485A1 CL2019003485A CL2019003485A CL2019003485A1 CL 2019003485 A1 CL2019003485 A1 CL 2019003485A1 CL 2019003485 A CL2019003485 A CL 2019003485A CL 2019003485 A CL2019003485 A CL 2019003485A CL 2019003485 A1 CL2019003485 A1 CL 2019003485A1
Authority
CL
Chile
Prior art keywords
nephropathy
immunoglobulin
methods
human subject
subject suffering
Prior art date
Application number
CL2019003485A
Other languages
Spanish (es)
Inventor
Gregory A Demopulos
Tom Dudler
Hans-Wilhelm Schwaeble
Nigel John Brunskill
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of CL2019003485A1 publication Critical patent/CL2019003485A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Abstract

EN UN ASPECTO, LA INVENCIÓN PROPORCIONA MÉTODOS PARA REDUCIR LA PROTEINURIA EN UN SUJETO HUMANO QUE PADECE, O ESTÁ EN RIESGO DE DESARROLLAR NEFROPATÍA POR INMUNOGLOBULINA A (IGAN); LOS MÉTODOS COMPRENDEN LA ETAPA DE ADMINISTRAR, A UN SUJETO QUE LO NECESITA, UNA CANTIDAD DE UN ANTICUERPO INHIBIDOR DE MASP-2 EFICAZ PARA INHIBIR LA ACTIVACIÓN DEL COMPLEMENTO MASP-2- DEPENDIENTE.IN ONE ASPECT, THE INVENTION PROVIDES METHODS FOR REDUCING PROTEINURIA IN A HUMAN SUBJECT SUFFERING FROM, OR AT RISK OF DEVELOPING IMMUNOGLOBULIN A NEPHROPATHY (IGAN); THE METHODS INCLUDE THE STAGE OF ADMINISTERING, TO A SUBJECT IN NEED, AN AMOUNT OF AN ANTIBODY INHIBITING MASP-2 EFFECTIVE TO INHIBIT THE ACTIVATION OF THE DEPENDENT MASP-2 COMPLEMENT.

CL2019003485A 2016-10-13 2019-11-28 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy. (divisional request 201900909) CL2019003485A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
CL2019003485A1 true CL2019003485A1 (en) 2020-04-13

Family

ID=61906454

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000909A CL2019000909A1 (en) 2016-10-13 2019-04-04 Methods to reduce proteinuria in a human subject suffering from immunoglobulin nephropathy a.
CL2019003485A CL2019003485A1 (en) 2016-10-13 2019-11-28 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy. (divisional request 201900909)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019000909A CL2019000909A1 (en) 2016-10-13 2019-04-04 Methods to reduce proteinuria in a human subject suffering from immunoglobulin nephropathy a.

Country Status (18)

Country Link
EP (1) EP3525798A4 (en)
JP (1) JP6893554B2 (en)
KR (1) KR102348939B1 (en)
CN (2) CN110177557A (en)
AU (1) AU2017342428B2 (en)
BR (1) BR112019007426A2 (en)
CA (2) CA3210384A1 (en)
CL (2) CL2019000909A1 (en)
GE (1) GEP20247587B (en)
IL (1) IL265981A (en)
JO (1) JOP20190068A1 (en)
MA (1) MA46541A (en)
MX (1) MX2019004074A (en)
PH (1) PH12019500711A1 (en)
SG (1) SG11201902941UA (en)
UA (1) UA126908C2 (en)
WO (1) WO2018071701A1 (en)
ZA (1) ZA201902933B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (en) * 2020-03-19 2020-07-17 长春市儿童医院 Glomerular lobular nephropathy modeling method
CN115215937B (en) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 Anti-human MASP-2 antibody, preparation method and application thereof
CN117016486B (en) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 Animal model construction method for IgA nephropathy combined membranous nephropathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374819B1 (en) * 2003-05-12 2017-03-22 Helion Biotech ApS Antibodies to MASP-2
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7626730B2 (en) 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
EP2488203B1 (en) * 2009-10-16 2016-12-07 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
WO2012100262A1 (en) * 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
JP5937197B2 (en) * 2011-04-08 2016-06-22 ユニバーシティー オブ レスター Methods for treating conditions associated with MASP-2-dependent complement activation
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
SI2704743T1 (en) * 2011-05-04 2020-08-31 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
US20150017162A1 (en) * 2013-03-15 2015-01-15 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
ES2829913T3 (en) * 2013-10-17 2021-06-02 Omeros Corp Treatment procedures for conditions associated with MASP-2-dependent complement activation
AU2017205453B2 (en) * 2016-01-05 2020-03-12 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
JOP20170170B1 (en) * 2016-08-31 2022-09-15 Omeros Corp Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

Also Published As

Publication number Publication date
CN116726163A (en) 2023-09-12
MA46541A (en) 2019-08-21
NZ753260A (en) 2021-11-26
BR112019007426A2 (en) 2019-07-02
UA126908C2 (en) 2023-02-22
CA3210384A1 (en) 2018-04-19
EP3525798A4 (en) 2020-07-08
ZA201902933B (en) 2023-05-31
GEP20247587B (en) 2024-01-25
CL2019000909A1 (en) 2019-06-14
WO2018071701A1 (en) 2018-04-19
JP6893554B2 (en) 2021-06-23
SG11201902941UA (en) 2019-05-30
IL265981A (en) 2019-06-30
PH12019500711A1 (en) 2019-11-18
MX2019004074A (en) 2019-06-10
AU2017342428A1 (en) 2019-05-23
EP3525798A1 (en) 2019-08-21
AU2017342428B2 (en) 2021-02-04
JP2019534271A (en) 2019-11-28
CA3039927A1 (en) 2018-04-19
JOP20190068A1 (en) 2019-04-01
KR102348939B1 (en) 2022-01-12
CA3039927C (en) 2023-10-10
CN110177557A (en) 2019-08-27
KR20190063475A (en) 2019-06-07

Similar Documents

Publication Publication Date Title
CL2019001411A1 (en) Methods for inhibition of fibrosis in a subject in need of them. (divisional application 201801817)
CL2017000558A1 (en) Combination therapy
CU24498B1 (en) FACTOR XI ANTIBODIES
CL2021000517A1 (en) Labeled antibody and / or fragment thereof comprising a monoclonal antibody or a fragment thereof, which specifically binds human tau; nucleic acid that encodes it; vector; cell; method of producing antibody; and use of the same to inhibit the aggregation of tau, and associated diseases (divisional application no. 202001003)
CR20190287A (en) (aza)indole-, benzothiophene-, and benzofuran-3-sulfonamides
CL2019003485A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy. (divisional request 201900909)
EA201892625A1 (en) COMBINED THERAPY WITH ACETYL-COA-CARBOXYLASE (ACC) INHIBITOR FOR THE TREATMENT OF A NON-ALCOHOLIC FATAL LIVER DISEASE DISEASE
CL2017001924A1 (en) Anti-transthyretin antibodies
BR112017005517A2 (en) antiage antibodies for the treatment of inflammation and autoimmune disorders
CO2017008469A2 (en) Anti-transthyretin antibodies
CL2016001979A1 (en) Methods of treating Alzheimer's disease.
CO2018005393A2 (en) Anti-htra1 antibodies and methods of use thereof
CR20160132A (en) COMPOSITIONS AND METHOD TO TREAT CONDITIONS ASSOCIATED WITH THE COMPLEMENT
CU20170098A7 (en) ANTI-TRANSTIRETINE ANTIBODIES
CO2021002954A2 (en) Anti-αvβ8 Antibodies and Compositions and Uses Thereof
BR112019001206A2 (en) humanized monoclonal antibodies targeting ve-ptp (hptp-ss)
MX2021005394A (en) Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies.
CO2022009696A2 (en) Anti-lilrb1 antibody and uses thereof
CO2022002627A2 (en) Biopharmaceutical compositions and related processes
CL2021002866A1 (en) Headache treatment using anti-cgrp antibodies.
BR112018012126A2 (en) "adjuvant, method for preventing and / or treating an autoimmune disease, and use of an adjuvant"
EA202191058A1 (en) ANTIBODIES AGAINST MUCIN-16 AND METHODS OF THEIR APPLICATION
BR112015023390A2 (en) Methods To Treat Kidney Disease And Other Disorders
EA201990903A1 (en) METHOD FOR REDUCING PROTEINURIA IN A HUMAN SUFFERING FROM IMMUNOGLOBULIN AND NEPHROPATHY
CL2020000397A1 (en) Highly concentrated low-viscosity masp-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome.